Breaking News Bar

Business News and Information

Why PhaseBio's stock rose 16 percent Tuesday

The Malvern biopharmaceutical company received an FDA designation that could accelerate the development of one of its lead new drug candidates.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear